BRAHMS KRYPTOR compact PLUS (instrument)

Device Brahms GmbH
Total Payments
$123,500
Transactions
22
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $18,000 3 0
2022 $21,500 5 0
2021 $30,000 5 0
2020 $30,000 5 0
2019 $24,000 4 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $123,500 22 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Chromogranin A as Surveillance biomarker in Patients with cARcinoids - the CASPAR study Brahms GmbH $63,500 0
various validation studies Brahms GmbH $24,000 0
CASPAR-study Reference Range study for chromogranin A and copeptin proAVP Brahms GmbH $12,000 0
Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnangy - PRAECIS Brahms GmbH $12,000 0
First Trimester Risk Assessment for Preeclampsia study (FITRAPS) Brahms GmbH $6,000 0
Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnangy - PRAECIS and First Trimester Risk Assessment for Preeclampsia study (FITRAPS) Brahms GmbH $6,000 0

Top Doctors Receiving Payments for BRAHMS KRYPTOR compact PLUS (instrument)

Doctor Specialty Location Total Records
Unknown Houston, TX $123,500 22

About BRAHMS KRYPTOR compact PLUS (instrument)

BRAHMS KRYPTOR compact PLUS (instrument) is a device associated with $123,500 in payments to 0 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Brahms GmbH.

Payment data is available from 2019 to 2023. In 2023, $18,000 was paid across 3 transactions to 0 doctors.

The most common payment nature for BRAHMS KRYPTOR compact PLUS (instrument) is "Unspecified" ($123,500, 100.0% of total).

BRAHMS KRYPTOR compact PLUS (instrument) is associated with 6 research studies, including "Chromogranin A as Surveillance biomarker in Patients with cARcinoids - the CASPAR study" ($63,500).